Paul Workman, Ph.D.
Professor Paul Workman FRS FMedSci
Paul Workman is the Harrap Professor of Pharmacology and Therapeutics and Leader of the Signal Transduction and Molecular Pharmacology Team at The Institute of Cancer Research (ICR), London. Until August 2021, he served for seven years as Chief Executive and President of ICR, and for almost twenty years he was Director of ICR’s Cancer Research UK (CRUK) Cancer Therapeutics Unit – one of the words leading academic drug discovery organizations. In addition, Paul served as Founding Director of the CRUK Convergence Science Centre at ICR and Imperial College, and he is Co-Director of the CRUK Children’s Brain Tumour Centre of Excellence at ICR and Cambridge University. Paul is an elected Fellow of the Royal Society (the UK’s national academy of science), Academy of Medical Sciences, Royal Society of Chemistry, Royal Society of Biology, Royal Society of Medicine, and European Academy of Cancer Sciences, and he was awarded a CRUK Life Fellowship.
Paul Workman is renowned for his research on the molecular pharmacology of targeted cancer drugs and he has been instrumental in the discovery of multiple clinical candidates and chemical probes, including those acting on protein kinases, PI3 kinases, the molecular chaperone HSP90 and the Heat Shock Factor 1 pathway. He is also the originator of the widely used Pharmacological Audit Trail for biomarker-led drug discovery and development. In addition, Paul has played a leading role in the provision of public resources for biomedical research and drug discovery, specifically the non-profit Chemical Probes Portal (of which he Executive Director), Probe Miner and canSAR.
Before joining ICR, Paul Workman spent four years in the cancer drug discovery leadership team at AstraZeneca, and prior to that worked at Glasgow and Cambridge Universities, with a sabbatical visit as a UICC Fellow to Stanford University and SRI International. Paul obtained his BSc in Biological Sciences from the University of Leicester, UK, and his PhD in Cancer Pharmacology from the University of Leeds, UK.
Paul Workman is also a serial scientific entrepreneur. He was a scientific founder of Piramed Pharma (acquired by Roche) and Chroma Therapeutics, has collaborated extensively with biotech and pharma companies, and serves as an adviser to several biotechs. As well as acting as a Science Partner at Nextech Invest, Paul is a Non-Executive Director at STORM Therapeutics and chairs STORM’s Scientific Advisory Board.
Paul Workman has received numerous honours and awards, including the Royal Society of Chemistry George and Christine Sosnovsky Award for Cancer Therapy, Royal Society of Chemistry World Entrepreneur Award, CRUK Translational Cancer Research Prize, and the International Raymond Bourgine Award for Excellence in Cancer Research. In addition, Paul led the team that won the 2012 American Association of Cancer Research Team Science Award, and under his leadership the ICR was awarded a 2017 Queens’ Anniversary Prize for its world-leading research in cancer drug discovery resulting in global patient impact. Paul lectures, writes and blogs about cancer research and drug discovery.